PDF herunterladen
Hamostaseologie 2022; 42(03): 180-184
DOI: 10.1055/a-1411-7807
Original Article

Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism

Abdulkerim Yıldız
1   Department of Hematology, Hitit University, Erol Olcok Training and Research Hospital, Corum, Turkey
,
Didem Katar
2   Department of Pulmonology, Yildirim Beyazit University, Yenimahalle Training and Research Hospital, Ankara, Turkey
,
Ayşe Özden Soydaş
3   Department of Biochemistry, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
,
Murat Albayrak
4   Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis and high levels may have an association with thrombosis. The aim of the current study was to investigate the association of TAFI antigen levels with pulmonary thromboembolism (PTE).

Patients and Methods A case–control study was conducted with 29 patients with PTE and 17 age- and gender-matched control individuals. Plasma levels of TAFI were measured at the time of diagnosis, then at 3 and 6 months after the event.

Results Initial TAFI levels (%) were higher in patients with PTE than in the control group (190,0 [65,0–250,0] vs 133,0 [83,0–153,0]; p = 0.003). TAFI levels significantly decreased at the third and sixth months after initial diagnosis (p < 0.05). The percentage reductions in TAFI levels were 12 and 36.8% at 3 and 6 months, respectively. The Odss ratio (OR) of TAFI level for PTE was found to be 1.024 (95% CI: 1.007–1.040; p = 0.005). There was no significant correlation of initial TAFI levels with age, gender, smoking status, history of thrombosis, pulmonary artery pressure, and D-dimer levels (p > 0.05). In the sixth month of treatment, patients with residual thrombosis were seen to have similar baseline levels and reductions of TAFI as patients without residual thrombosis (p > 0.05).

Conclusion The result of this study suggests that high TAFI levels may have a role in the occurrence of PTE without impact on treatment outcome.

Keywords

TAFI - pulmonary thromboembolism - association


Publikationsverlauf

Eingereicht: 05. September 2020

Angenommen: 04. März 2021

Artikel online veröffentlicht:
17. Juni 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Rosovsky R, Zhao K, Sista A, Rivera-Lebron B, Kabrhel C. Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost 2019; 3 (03) 315-330
    CrossrefPubMedGoogle Scholar
  • 2 Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?. J Thromb Haemost 2009; 7 (12) 1962-1971
    CrossrefPubMedGoogle Scholar
  • 3 Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43 (02) 178-184
    PubMedGoogle Scholar
  • 4 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270 (24) 14477-14484
    CrossrefPubMedGoogle Scholar
  • 5 Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004; 11 (17) 2335-2348
    CrossrefPubMedGoogle Scholar
  • 6 Bavbek N, Ceri M, Akdeniz D. et al. Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients. Ren Fail 2014; 36 (05) 743-747
    CrossrefPubMedGoogle Scholar
  • 7 Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101 (12) 4844-4846
    CrossrefPubMedGoogle Scholar
  • 8 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95 (09) 2855-2859
    CrossrefPubMedGoogle Scholar
  • 9 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 10 Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J Thromb Haemost 2003; 1 (03) 492-493
    CrossrefPubMedGoogle Scholar
  • 11 Radu CM, Spiezia L, Campello E, Gavasso S, Woodhams B, Simioni P. Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. Thromb Res 2013; 132 (04) 484-486
    CrossrefPubMedGoogle Scholar
  • 12 Libourel EJ, Bank I, Meinardi JR. et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87 (10) 1068-1073
    PubMedGoogle Scholar
  • 13 Silveira A, Schatteman K, Goossens F. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84 (03) 364-368
    PubMedGoogle Scholar
  • 14 Leenaerts D, Bosmans JM, van der Veken P, Sim Y, Lambeir AM, Hendriks D. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction. J Thromb Haemost 2015; 13 (12) 2227-2232
    CrossrefPubMedGoogle Scholar
  • 15 Bridge KI, Bollen L, Zhong J. et al. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease. J Thromb Haemost 2017; 15 (11) 2218-2225
    CrossrefPubMedGoogle Scholar
  • 16 Donmez A, Aksu K, Aydin H. et al. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis. Thromb Res 2010; 126 (03) 207-210
    CrossrefPubMedGoogle Scholar
  • 17 Erdogan M, Solmaz S, Canataroglu A. et al. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers. Endocrine 2010; 37 (03) 449-454
    CrossrefPubMedGoogle Scholar
  • 18 Eser M, Kement M, Balin S. et al. Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer. World J Surg Oncol 2012; 10: 180
    CrossrefPubMedGoogle Scholar
  • 19 Grosso G, Vikerfors A, Woodhams B. et al. Thrombin activatable fibrinolysis inhibitor (TAFI)—a possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). Thromb Res 2017; 158 (158) 168-173
    CrossrefPubMedGoogle Scholar
  • 20 Yaoita N, Satoh K, Satoh T. et al. Thrombin-activatable fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2016; 36 (06) 1293-1301
    CrossrefPubMedGoogle Scholar
  • 21 Zidane M, de Visser MC, ten Wolde M. et al. Frequency of the TAFI-438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost 2003; 90 (03) 439-445
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 22 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98 (06) 1992-1993
    CrossrefPubMedGoogle Scholar
  • 23 Declerck PJ. Thrombin activatable fibrinolysis inhibitor. Hamostaseologie 2011; 31 (03) 165-166 , 168–173
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Denorme F, Wyseure T, Peeters M. et al. Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice. Stroke 2016; 47 (09) 2419-2422
    CrossrefPubMedGoogle Scholar
  • 25 Zhou J, Kochan J, Yin O. et al. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. J Thromb Haemost 2017; 15 (05) 961-971
    CrossrefPubMedGoogle Scholar